One of the scariest words a person can hear is a cancer diagnosis. But the most important truth in urology is this: the majority of urological cancers are highly curable when found early. Stage 1 kidney cancer has a survival rate of over 92%. Testicular cancer at any stage is one of the most curable cancers in all of oncology. Even bladder cancer, notorious for its high rate of recurrence, can be effectively managed for years with appropriate surveillance and treatment.
Urological cancers including those of kidney, prostate, bladder, testis and penis constitute a significant proportion of all cancers in India. What they have in common is that early detection matters: The same cancer that is completely curable when detected early can be much more difficult to treat if allowed to progress.
Cancer is caused by genetic mutations, changes in the DNA, of cells in an organ that cause them to grow out of control, invade surrounding tissue and possibly spread to other parts of the body via the lymphatics or bloodstream. A tumour is simply an abnormal mass of tissue. It is important to realise that not all tumours are malignant (cancerous). Benign (non-cancerous) tumours grow locally do not spread Malignant tumours invade adjacent structures and can metastasise.
Urological cancers are those that develop in the organs of the genitourinary tract: the kidneys, ureters, bladder, prostate, testis and penis. Each has different risk factors, presentation patterns, diagnostic workup, and treatment approaches. What they have in common is the critical importance of early detection. Many urological cancers are asymptomatic in their earliest, most curable stages, highlighting the importance of regular health screenings (especially PSA testing for prostate cancer) for men over the age of 50.
Here is a concise overview of each urological cancer treated by Dr. Vikas Singh, with links to the dedicated sub-service pages for full clinical detail:
Kidney Cancer (Renal Cell Carcinoma)
The most common type of kidney cancer, originating in the cells of the renal tubule. Most are diagnosed incidentally on ultrasound before symptoms develop. Stage 1 five-year survival >92%. Treated with laparoscopic partial or radical nephrectomy.
Most common urological cancer in men. Usually diagnosed based on increased PSA levels before symptoms occur. Range from slow growing tumours suitable for surveillance to aggressive disease requiring surgery, radiation or hormone therapy.
Begins in the bladder’s urothelial lining. Usually presents with painless blood in the urine. 75-80% are non-muscle invasive at diagnosis , treated with TURBT and intravesical therapy . Cystectomy is required for muscle-invasive disease.
Affects mainly males 15-35 years old. Presents as a painless hard lump in the testis. Exceedingly chemosensitive, Stage 1 cure rate > 99%, Stage 3 cure rate > 90%. Fast assessment needed; sperm banking before treatment essential.
Squamous cell carcinoma of the penis, usually involving the glans and foreskin Phimosis and lichen sclerosus. Associated HPV. Early-stage disease is curable with organ-preserving surgery. The most dangerous risk factor is delay driven by stigma.
Understanding risk factors allows for targeted screening and lifestyle modification , the two most powerful tools for reducing urological cancer burden:
Smoking & Tobacco Use (Bladder & Kidney Cancer)
Cigarette smoking is the most important modifiable risk factor for bladder cancer, accounting for approximately 50% of cases in men. Kidneys filter out tobacco carcinogens and concentrate them in the urine, where they are in prolonged contact with the lining of the bladder. Smoking also greatly increases the risk of kidney cancer (about 50% compared to non-smokers) due to direct carcinogenic effects on renal tubular cells. Stopping smoking at any age gradually lowers the risk of urological cancer and is the most effective single cancer prevention measure a smoker can take.
Age is the most important non-modifiable risk factor for most urological cancers. The risk of developing prostate cancer increases dramatically after the age of 50, the risk of kidney cancer increases after 55, and the risk of bladder cancer increases after 60. Having a first-degree relative (father or brother) with prostate cancer increases a man’s own risk twofold and warrants starting PSA screening at age 45 instead of age 50 years. Hereditary conditions, especially BRCA2 mutations (associated with aggressive prostate cancer), VHL syndrome (associated with clear cell kidney cancer) and Lynch syndrome (associated with upper tract urothelial cancer) require genetic counselling and earlier, more intense surveillance.
Human Papilloma Virus ( HPV ) , particularly the high-risk types HPV-16 and HPV-18 , accounts for approximately 40-50% of penile squamous cell carcinomas . HPV is sexually transmitted with risk factors including multiple sexual partners and early age of sexual activity. HPV vaccination of adolescent boys before the start of sexual activity significantly reduces the risk of HPV-associated penile cancer . HPV has also been associated with a proportion of bladder cancers, although the evidence is less clear than for penile cancer.
Obesity is a major risk factor for kidney cancer . Overweight and obese persons are at a 20 to 84% increased risk of renal cell carcinoma compared with normal-weight persons through mechanisms including increased levels of insulin, oestrogen and adipokines that induce aberrant cell growth . Obesity is also linked to increased PSA levels and increased risk of prostate cancer progression, which further complicates the interpretation of prostate cancer screening. Population studies have indicated a link between regular physical activity (150 minutes per week of moderate-intensity exercise) and a decreased risk of kidney and bladder cancer.
Men with chronic kidney disease (CKD) and those on long-term haemodialysis have a markedly increased risk of developing acquired cystic kidney disease . Multiple cysts develop in the native kidneys , which carries with it an increased risk of renal cell carcinoma. Patients on long-term dialysis need periodic ultrasound surveillance of the native kidneys for early detection of renal masses. A kidney transplant greatly reduces (but does not eliminate) this risk.
Smoking is a known risk factor for bladder cancer, and so is occupational exposure to aromatic amines, which are used in the dye, rubber, leather, printing and hairdressing industries. Workers in these industries have 2 to 7 times the risk of bladder cancer compared with the general population. The latency period for developing cancer can be 20 to 40 years, so current diagnoses of cancer in older workers may be related to exposures that occurred decades ago. Urgent cystoscopy should be considered in any man with a history of occupational exposure to aromatic amines, who has urinary symptoms (particularly blood in urine).
The most important factor in selecting treatment and predicting prognosis is the stage of the cancer, or how far it has spread. All urological cancers are staged using the TNM (Tumour, Node, Metastasis) system. Here’s a generalised overview of what each stage means across urological cancers:
Stage 1 , Cancer Confined to Organ of Origin
The cancer is confined only to the organ of origin , kidney capsule , prostate gland , bladder wall surface , testis , and has not spread to any lymph nodes or distant organs . Stage 1 urological cancers have the highest cure rates . These are over 90 to 99% for testicular cancer , over 92% for kidney cancer and over 95% for prostate cancer . Stage 1 is the best and least invasive form of treatment.
The cancer is larger or more locally advanced than Stage 1 but has not spread outside the organ or to lymph nodes. Stage 2 urologic cancers are still potentially curable in most patients with definitive treatment , which may be surgery , radiation , or combination therapy depending on the type of cancer.
The cancer has grown into nearby tissues or has invaded nearby structures or spread to regional lymph nodes. Stage 3 urological cancers require more complex treatment, combinations of surgery, chemotherapy, radiation or hormone therapy. Even in stage 3, many patients can still be cured, especially if aggressive, well-planned multidisciplinary management is used.
Cancer has spread to distant organs like the lungs, bones, liver and brain. Stage 4 urological cancer is generally not curable with traditional treatment, but that meaningful disease control and prolonged survival can be achieved with modern systemic therapies, targeted agents, immunotherapy and hormone therapy. Testicular cancer is a special exception . Even metastatic ( Stage 4 ) testicular cancer is curable in the majority of good-prognosis patients with cisplatin-based chemotherapy .
Prostate cancer is the commonest urological cancer in adult males in India and incidence is increasing significantly with the increase in population aging and PSA awareness. Bladder cancer is the second most common type, followed by kidney cancer. Testicular cancer is the most common solid organ cancer in men aged 15 to 35 years of age, but it is relatively rare. Penile cancer is rare by world standards, but its incidence is higher in India than in Western countries because of lower rates of circumcision, the prevalence of HPV and the delay in diagnosis due to stigma.
Not always , but always it should be looked into . Common causes of blood in urine (haematuria) include urinary tract infections, kidney stones or benign prostate hyperplasia. But it is also the most common early symptom of bladder cancer and kidney cancer. Crucially, bleeding from cancer is often painless and intermittent, may appear once, disappear for weeks, and then reappear. Any visible blood in urine in an adult, even once, even without pain, merits urgent urological evaluation including cystoscopy and upper tract imaging to exclude malignancy.
Annual PSA testing is recommended from age 50 for average-risk men, and from age 45 for men with a first-degree relative (father or brother) who had prostate cancer, or for men of African descent (who have inherently higher risk). PSA is a simple blood test that can detect prostate cancer when it is still confined to the gland, the most curable phase of the disease. Dr. Vikas Singh is a big advocate of using PSA screening as a standard part of men’s annual health checks, beginning at these ages.
While no cancer is completely preventable, several evidence-based measures significantly reduce the risk of urological cancer: quitting smoking (reduces bladder and kidney cancer risk); maintaining a healthy weight (reduces kidney cancer risk); HPV vaccination in adolescent boys (reduces penile cancer risk); early circumcision for men with phimosis (reduces penile cancer risk); annual PSA testing from age 50 (allows early detection of prostate cancer); monthly testicular self-examination from puberty (allows early detection of testicular cancer); minimising occupational chemical exposure; and regular ultrasound surveillance for men on long-term dialysis.
No, most early stage urological cancers are treated by surgery alone. Stage 1 kidney cancer: laparoscopic nephrectomy or partial nephrectomy. No chemotherapy or radiation is necessary. Stage 1 and 2 prostate cancer. Surgery or radiation, no chemo. Stage 1 testicular cancer (orchiectomy only with or without adjuvant carboplatin): no chemotherapy in most cases. Stage 1 bladder cancer – TURBT and intravesical BCG or chemotherapy, systemic chemotherapy only for muscle-invasive disease. We reserve chemotherapy for higher stage disease, for metastatic cancers, and for some situations where the evidence supports its use.
This can vary depending on the type of cancer and surgery. Laparoscopic partial nephrectomy (kidney): 90-150 minutes; discharge in 2-3 days; return to work in 2-3 weeks. Laparoscopic radical prostatectomy: 2-3 hours; discharge in 3 days; return to work in 2-3 weeks. TURBT (bladder) 30 to 60 minutes. Discharge in 1 to 2 days. Return to light work in 3 to 5 days. Radical orchiectomy (testis) 30-45 minutes Discharge next day Return to work 1-2 weeks Laparoscopic radical cystectomy (bladder, muscle-invasive). 4 to 6 hours; discharge in 5 to 7 days; return to light work in 4 to 6 weeks.
Second opinion – Your diagnosis, staging and proposed treatment plan are reviewed by another specialist to confirm the recommendation or suggest an alternative approach. Dr. Vikas Singh recommends that people get a second opinion for cancer. Specialist review improves urological cancer management, especially the decision between radical and partial nephrectomy, radical cystectomy vs bladder preservation, and the choice of systemic therapy for advanced disease. Dr. Vikas Singh gives second opinions and he makes very detailed and honest evaluations.
24/7 Services Available
Copyright © 2026 Urology Center | All Rights Reserved
Design and Developed by Namastetu Technologies Pvt.Ltd
